Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on issuance of convertible debentures | NaN | 0 | 0 | 0 |
| Gain on high trail extinguishment | NaN | 0 | 0 | 0 |
| Loss on extinguishment of convertible debentures payable | NaN | 0 | NaN | NaN |
| Disposal of internal-use software | NaN | 0 | 0 | NaN |
| Intangible assets and other long-lived assets impairment | NaN | 0 | 0 | 0 |
| Gain on lease termination/modification | NaN | NaN | 0 | 450 |
| Net realized loss on investments | NaN | 0 | 0 | 0 |
| Net loss | -8,303 | -7,933 | -8,504 | -9,958 |
| Depreciation and amortization expense | 2,310 | 2,337 | 2,376 | 4,814 |
| Inventory write-offs | NaN | 0 | 0 | NaN |
| Change in fair value of contingent consideration | NaN | 0 | 0 | 0 |
| Amortization of financing lease right-of-use asset | 51 | 51 | 51 | 102 |
| Accretion of interest on securities | 194 | 249 | 236 | 491 |
| Non-cash lease expense | 122 | -81 | 392 | 582 |
| Gain on lease modification | 0 | 450 | NaN | NaN |
| Stock-based compensation | 670 | 926 | 941 | 2,667 |
| Long-lived assets held for sale impairment | NaN | 0 | NaN | NaN |
| Cost of leased equipment sold to customer | 50 | 356 | 133 | 215 |
| Right-of-use-asset impairment | NaN | 0 | 0 | NaN |
| Change in fair value of convertible debentures | -173 | -154 | 62 | 5,250 |
| Disposal of property and equipment | -34 | 0 | 0 | -258 |
| Other assets | NaN | NaN | -326 | -666 |
| Accounts receivable | -1,067 | 674 | 1,031 | -1,257 |
| Inventory | 106 | -1,574 | -1,508 | -1,834 |
| Prepaid expenses and other current assets | -339 | -173 | 2,280 | -45 |
| Other long-term assets | -16 | -60 | NaN | NaN |
| Accounts payable | -528 | -399 | -254 | -719 |
| Accrued expenses, contract liabilities, and lease liabilities, net | -1,417 | 522 | 721 | -1,823 |
| Net cash used in operating activities | -5,716 | -4,175 | -5,919 | -6,251 |
| Purchases of property and equipment | NaN | 0 | 0 | 0 |
| Purchase of available for sale securities | 48,672 | 64,352 | 60,885 | 116,642 |
| Sale and maturities of available for sale securities | 54,129 | 68,361 | 56,216 | 104,555 |
| Debt issuance costs on sale of convertible debentures | NaN | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | 5,457 | 4,009 | -4,669 | -12,087 |
| Principal payments of financing lease liability | 20 | 18 | 19 | 34 |
| Proceeds from sale of common stock and warrants | 705 | 1,751 | 12,939 | 16,408 |
| Proceeds from issuance of convertible debentures | NaN | 0 | 0 | 0 |
| Offering expenses on sale of common stock and warrants | 28 | 130 | 969 | 1,023 |
| Proceeds from sale of common stock under employee stock purchase plan | NaN | 0 | 0 | 0 |
| Payments on high trail notes | NaN | 0 | 0 | 0 |
| Proceeds from warrant and option exercises | 0 | 0 | 0 | 9 |
| Payments of retirement fees for redemption of high trail notes | NaN | 0 | 0 | NaN |
| Payments on convertible debentures | 0 | 0 | 1,875 | 3,000 |
| Net cash provided by financing activities | 657 | 1,603 | 10,076 | 12,360 |
| Effect of exchange rates on cash and cash equivalents and restricted cash | 5 | 7 | 15 | -33 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 403 | 1,444 | -497 | -6,011 |
| Cash and cash equivalents and restricted cash at beginning of period | 4,509 | 3,065 | 9,573 | NaN |
| Cash and cash equivalents and restricted cash at end of period | 4,912 | 4,509 | 3,065 | NaN |